Advances in Equine Oncology: Causes, Molecular Changes, Clinicopathologic and Treatment

A special issue of Animals (ISSN 2076-2615). This special issue belongs to the section "Equids".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 1020

Special Issue Editor


E-Mail Website
Guest Editor
Department of Animal Molecular Biology, National Research Institute of Animal Production, Krakowska 1 St., 32-083 Balice, Poland
Interests: equine; tumor; veterinary oncology; next generation sequencing; genomics; transcriptomics; epigenomics; gene expression; methylation; miRNA; biomarkers; diagnosis; therapy

Special Issue Information

Dear Colleagues,

The continuous importance of horses in sport, recreation, or as a workforce in underdeveloped countries has brought about an increasing need to update and expand the knowledge about equine diseases, including cancer. The research on cancer in horses and other equids is substantially less advanced than in other companion animal species. Despite this, neoplasia in equids is a common problem. Currently, advances in molecular biology and DNA sequencing provide an opportunity to determine the molecular profile of any cancer by enabling for the identification of specific mutations that occur in DNA or changes that arise at the epigenome level. Based on this overall picture, targeted treatment or immunotherapy can be applied by matching the molecular profile of the individual's cancer.

Therefore, this Special Issue aims to publish original research papers or reviews addressing the molecular mechanisms in tumor initiation, maintenance, and progression in Equidae, taking into account their diagnosis and new treatment methods.

Dr. Ewelina Semik-Gurgul
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Animals is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • equine
  • tumor
  • veterinary oncology
  • next generation sequencing
  • genomics
  • transcriptomics
  • epigenomics
  • gene expression
  • methylation
  • miRNA
  • biomarkers
  • diagnosis
  • therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 4109 KiB  
Article
Programmed Cell Death-Ligand 1 (PD-L1) Immunohistochemical Expression in Equine Melanocytic Tumors
by José Pimenta, Justina Prada, Isabel Pires and Mário Cotovio
Animals 2024, 14(1), 48; https://doi.org/10.3390/ani14010048 - 22 Dec 2023
Cited by 2 | Viewed by 831
Abstract
Currently available treatments for equine melanocytic tumors have limitations, mainly due to mass localization and dimension, or the presence of metastases. Therefore, a search for new therapies is necessary. Programmed cell death-ligand 1 (PD-L1) is expressed by several tumors, blocking T cell-mediated elimination [...] Read more.
Currently available treatments for equine melanocytic tumors have limitations, mainly due to mass localization and dimension, or the presence of metastases. Therefore, a search for new therapies is necessary. Programmed cell death-ligand 1 (PD-L1) is expressed by several tumors, blocking T cell-mediated elimination of the tumor cells by binding to programmed cell death protein 1 (PD-1). A novel therapeutic approach using PD-1/PD-L1 blockade in human melanoma resulted in tumor regression and prolonged tumor-free survival. This study aimed to evaluate the immunohistochemical expression of PD-L1 in equine melanocytic tumors. A total of 77 melanocytic tumors were classified as benign or malignant and evaluated by extension of labeling. A total of 59.7% of the tumors showed >50% of immunolabeled cells. Regarding malignant tumors, 24/38 tumors presented >50% of labeled cells, 13 tumors presented between 25–50% and one tumor presented <10%. Regarding benign tumors, 22/39 tumors presented >50% of labeled cells, nine tumors presented 25–50%, three tumors presented 10–25%, two tumors presented <10% and three tumors did not present expression. Our results suggest that PD-L1 blockade may be a potential target for immunotherapy in equine melanocytic tumors and that future clinical research trials into the clinical efficacy of the anti-PD-L1 antibody are necessary. Full article
Show Figures

Figure 1

Back to TopTop